Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Iran J Basic Med Sci ; 22(10): 1186-1191, 2019 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-31998461

RESUMEN

OBJECTIVES: This study investigated the role of locus coeruleus (LC) nucleus TRPV1 receptors (TRPV1r) in the expression and development of morphine physical dependence by intra-LC administration of AMG9810 (selective TRPV1r antagonist) in male Wistar rats. MATERIALS AND METHODS: For assessing the development of morphine dependence, AMG9810 (0.03 and 0.3 mM in 10% DMSO, 0.2 µl; intra-LC microinjection) was administered before each morphine administration for seven continues days (once daily; 6, 16, 26, 36, 46, 56, and 66 mg/kg; sc). Furthermore, for evaluating the expression of morphine dependence, a single dose of AMG9810 (0.03 and 0.3 mM in 10% DMSO, 0.2 µl; intra-LC microinjection) was administered to morphine-dependent rats on day 8 of the experiment. RESULTS: Obtained data demonstrated that co-administration of TRPV1r antagonist with morphine reduced the development of morphine withdrawal syndrome somatic signs induced by naloxone. Moreover, single intra-LC administration of TRPV1r antagonist on the final day of the examination period significantly decreased the expression of some signs of morphine withdrawal in rats. CONCLUSION: The results showed that LC TRPV1r might be participating in the expression and development of morphine dependence.

2.
Neurol Res ; 39(9): 845-851, 2017 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-28701075

RESUMEN

OBJECTIVE:  The aim of this study was to evaluate the effect of orexin-A (OX-A) and the orexin-1 receptor antagonist SB-334867 (SB) on motor and cognitive functions in a rat model of Parkinson's disease. METHODS: Parkinson was induced by intracerebroventricular (i.c.v) injection of 6- hydroxydopamine (6-OHDA) (200 µg/rat). 72 h later, the treatment was initiated by i.c.v administration of SB (30 nmol/rat) and/or OX-A (0.3 nmol/rat) for 10 days. Motor functions were monitored using rotarod and hanging tests. Cognitive function was assessed by passive avoidance test (Shuttle box). Results: OX-A administration in 6-OHDA treated rats remarkably increased the time which animals run on rod (in rotarod test) and also the latency to fall (in hanging test) (P < 0.01 and P < 0.001, respectively). Conversely, administration of SB in 6-OHDA-treated rats decreased the mentioned indices (P < 0.05 for latency to fall). Administration of agonist and/or antagonist of orexin-1 receptors had no significant effect on 6-OHDA induced cognitive impairment in rats. CONCLUSION:  Results of this study suggest that the orexinergic system might be involved in sensory-motor deficits of Parkinson's disease.


Asunto(s)
Trastornos del Conocimiento/tratamiento farmacológico , Trastornos del Conocimiento/etiología , Actividad Motora/efectos de los fármacos , Orexinas/uso terapéutico , Enfermedad de Parkinson/complicaciones , Animales , Reacción de Prevención/efectos de los fármacos , Modelos Animales de Enfermedad , Masculino , Microinyecciones , Fuerza Muscular/efectos de los fármacos , Orexinas/farmacología , Oxidopamina/toxicidad , Enfermedad de Parkinson/etiología , Ratas , Ratas Wistar , Prueba de Desempeño de Rotación con Aceleración Constante , Estadísticas no Paramétricas
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA